Medunik Canada obtains new Notice of Compliance from Health Canada for Ruzurgi® (amifampridine) following a favourable Canadian Federal Court of Appeal ruling
BLAINVILLE (Quebec), January 17, 2023 -- Medunik Canada Inc. (“Medunik”), a company dedicated to improving the health and quality of life of Canadians with rare diseases by bringing orphan drugs to Canada, is pleased to announce that on January 9, 2023, the Federal Court of Appeal of Canada set aside an earlier decision of its Trial Division which had removed a Notice of Compliance on Medunik’s Ruzurgi® (amifampridine) for Lambert-Eaton Myasthenic Syndrome ("LEMS") patients and sent the matter back to Health Canada.